Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MM 09

Next Previous
Drug Profile

MM 09

Alternative Names: Dermatophagoides farinae/Dermatophagoides pteronyssinus allergen immunotherapy - Inmunotek; House dust mite allergen extract - Inmunotek; House dust mite allery immunotherapy D. pteronyssinus/D. farinae - Inmunotek; M-601/M-602; M-602/M-601; MM09; MM09-I/MM09-II; MM09-II/MM09-I; Polymerised-allergoids conjugated to nonoxidised- mannan

Latest Information Update: 13 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inmunotek
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinitis; Asthma
  • Phase II Hypersensitivity

Most Recent Events

  • 19 Dec 2023 Inmunotek terminates a phase III trial in Asthma and Allergic rhinitis (In adults, In the elderly) in Spain (SC) due to due to the low recruitment rate since the start of the trial (NCT04874714)
  • 13 Dec 2022 Inmunotek plans a phase II/III trial for Allergic rhinitis, Allergic asthma, Allergic rhinoconjunctivitis, Hypersensitivity (In Children, In adults) in Argentina (Sublingual) (NCT05641272)
  • 02 Jun 2022 Inmunotek plans a phase III trial for Allergic asthma and Rhinitis/rhinoconjunctivitis (In child, In adult) in Spain (SC) in August 2022 (NCT05400811)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top